Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off,Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage
Restricted accessCase reportFirst published online March, 2025
Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off,Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage
Purpose: To evaluate the use of antivascular endothelial growth factor (anti-VEGF) as treatment for tractional retinal detachments (TRDs) involving the macula. Methods: A case report was evaluated. Results: A 40-year-old man with a medical history notable for congenital heart disease and proliferative diabetic retinopathy presented with decreased vision. Surgery was not feasible for medical reasons, and panretinal photocoagulation was limited by retinal traction and hemorrhage. Despite initial progression of bilateral macula-off, foveal-on TRDs, the patient received intravitreal (IVT) bevacizumab regularly every 8 to 12 weeks. After initial improvement, both eyes remained anatomically stable with attached foveas over more than 1.5 years of follow-up. Conclusions: In cases in which surgery is not possible, macula-involving TRDs with neovascularization can be managed successfully with repeated IVT anti-VEGF injection monotherapy.
EliottDHemeidaT.Diabetic traction retinal detachment. Int Ophthalmol Clin. 2009;49(2):153-165.
2.
SokolJTSchechetSARosenDTFerenchakKDawoodSSkondraD.Outcomes of vitrectomy for diabetic tractional retinal detachment in Chicago’s county health system. PLoS One. 2019;14:e0220726.
3.
KhanMAKuleyARiemannCD, et al. Long-term visual outcomes and safety profile of 27-gauge pars plana vitrectomy for posterior segment disease. Ophthalmology. 2018;125:423-431.
4.
StewartMWBrowningDJLandersMB.Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66:1751-1762.
5.
BerrocalMHAcaba-BerrocalLAcabaAM.Long-term outcomes of same patient eyes treated with pars plana vitrectomy in one eye and conventional treatment in the other for complications of proliferative diabetic retinopathy. J Clin Med. 2022;11:5399.
6.
StoreyPPTer-ZakarianAPhilanderSA, et al. Visual and anatomical outcomes after diabetic traction and traction-rhegmatogenous retinal detachment repair. Retina. 2018;38:1913-1919.
7.
ShroffCMGuptaCShroffDAtriNGuptaPDuttaR.Bimanual microincision vitreous surgery for severe proliferative diabetic retinopathy: outcome in more than 300 eyes. Retina. 2018;38(suppl 1):S134-S145.
AhnJWooSJChungHParkKH.The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118:2218-2226.
10.
Al-KharashiAGalbinurTMandelcornEDMuniRHNabaviMKertesPJ.The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy. Saudi J Ophthalmol. 2016;30:217-220.
11.
SohnEHHeSKimLA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol. 2012;130:1127-1134.
12.
MuraliASharmaAMoloneyTP. Macula involving tractional retinal detachment after intravitreal ranibizumab – a case of crunch. Research Square; 2022. doi:10.21203/rs.3.rs-1772470/v. Accessed January 28, 2024. https://www.researchsquare.com/article/rs-1772470/v1
13.
TanYFukutomiASunMTDurkinSGilhotraJChanWO.Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review. Surv Ophthalmol. 2021;66:926-932.
14.
Torres-SorianoMEReyna-CastelánEHernández-RojasM, et al. Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep. 2009;3:70-73.
15.
ArevaloJFMaiaMFlynnHW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213-216.
16.
ArevaloJFSanchezJGSaldarriagaL, et al. Retinal detachment after bevacizumab. Ophthalmology. 2011;118:2304.e3-2304.e7.
17.
MoradianSAhmadiehHMalihiMSoheilianMDehghanMHAzarminaM.Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1699-1705.
18.
OshimaYShimaCWakabayashiT, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927-938.
19.
MahmoudzadehRWilliamsonJESalabatiM, et al. OCT-based description of spontaneous reattachment of macula-off tractional retinal detachment with significant vision improvement. J Vitreoretin Dis. 2024;8:101-104.
TasmanW.Retinal detachment secondary to proliferative diabetic retinopathy. Arch Ophthalmol. 1972;87:286-289.
22.
LeeITCoronaSTWongTPFlynnHWJrWykoffCC.Favorable anti-VEGF crunch syndrome: nonsurgical relief of vitreoretinal traction in eyes with proliferative diabetic retinopathy and tractional retinal detachment. Ophthalmic Surg Lasers Imaging Retina. 2022;53:455-459.
23.
AdamisAPMillerJWBernalM-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
24.
KrollPRodriguesEBHoerleS.Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica. 2007;221:78-94.
25.
FaulbornJBowaldS.Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: corresponding light and electron microscopic studies. Graefes Arch Clin Exp Ophthalmol. 1985;223:130-138.
26.
SchwartzSDAlexanderRHiscottPGregorZJ.Recognition of vitreoschisis in proliferative diabetic retinopathy: a useful landmark in vitrectomy for diabetic traction retinal detachment. Ophthalmology. 1996;103:323-328.
